Over the past 10 years more than 10,000 papers and in vitro investigations have been published that identify or analyse various critical pathways and biological processes through which the phytoalexin resveratrol has been shown to attenuate the metabolic dysfunctions, acute symptomatology and the consequential downstream pathologies related to type 2 diabetes. More recently, several clinical trials have confirmed resveratrol's potential to substantially enhance the therapeutic effects of the pharmaceutical metformin hydrochloride, particularly related to glucose management, insulin sensitivity and cardioprotection. Metformin is the most commonly prescribed type 2 diabetes treatment worldwide; consequently, any compound with the ability to safely and effectively augment its therapeutic effects warrants intensive investigation. This paper elucidates the principal modes of action that underly resveratrol's promising potential as an effective adjunct treatment for patients currently being administered metformin.
biological mechanisms at the cellular and extracellular levels that have been identified as having chemopreventive properties with respect to a significant number of chronic diseases, particularly those commonly associated with ageing and obesity. 16, 17 Moreover, resveratrol's ability to activate sirtuins 1-7 (SIRT1-7), particularly SIRT1, a prolific, highly conserved NAD+-dependent lysine deacylase, 18 either indirectly via the intermediary coenzyme NAD+ at low doses, or directly at high doses, identifies this molecule as a prime candidate for adoption as a potential pharmacological agent targeted towards the cellular and extra-cellular dysfunctions and abnormalities underlying type 2 diabetes, obesity and other mitocondrial-mediated metabolic pathologies. Given the low level of patient compliance with behaviour-modification-based type 2 diabetes remedial strategies, such as diet and regular vigorous physical exercise, 19 clearly there exists a mandate for development of nontoxic, efficacious and affordable treatments to stem the accelerating escalation in the incidence of this disease worldwide. Table 1 summarises some of the recent cell culture and animal studies that have been undertaken on the benefits of treating diabetes and its accompanying complications with resveratrol. The data clearly reveal several clinically relevant aspects. Among the major findings are that chronic resveratrol administration provides a safe approach to reduce chronic inflammatory properties associated with obesity while restoring insulin responsiveness in visceral white adipose tissue (WAT), 20 attenuates the inflammatory injury of the vascular wall, 21 attenuates methylglyoxal (MG)-induced oxidative stress in pancreatic cells with increase in insulin levels, 22 reduces oxidative-stress obesity pathologies and improves glucose tolerance. 23 Resveratrol attenuates b-cell loss, inhibits oxidative stress, improves glucose tolerance, 24 decreases plasma glucose levels, potentiates lipid metabolism, improves b-cell mass lipid content and diminishes oxidative stress, in addition to promoting SIRT1 expression. Furthermore, resveratrol effectively reduces reactive oxidative stress (ROS) and maintains mitochondrial function and enhances mitogenesis via SIRT1 activation.
This extensive constellation of actions elucidate resveratrol's promise as a pharmacological agent to treat diabetic nephropathy, [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] protect against hepatic and renal damage induced by oxidative stress, 27 mediate high-glucose (HG)-induced superoxide production, modulate FOXO3a expression and protect p47phox monocytes against oxidative stress in HG conditions. 28 Resveratrol restores the diminished expression of nephrin in the kidneys of people with diabetes to normal levels and decreases plasma glucose levels, lipid metabolism, b-cell mass lipid content and oxidative stress damage, in addition to promoting SIRT1 expression islets. Resveratrol could thus be a new therapeutic agent for retarding the progression of early diabetic nephropathy. 29 It also shows hepatocyte-protection activity through the attenuation of the markers of hyperglycaemia-mediated oxidative stress without affecting normal cellular function and structural integrity. Table 2 summarises the clinical studies that have been carried out so far on the benefits of resveratrol in treating diabetes and its accompanying complications, as well as studies in obese patients who are at risk of type 2 diabetes. The data reveal that long-term supplementation with grape extract containing a small quantity of resveratrol has a beneficial immunomodulatory effect on hypertensive patients with type 2 diabetes. 31 Resveratrol supplementation has benefits in type 2 diabetes patients, including lowering of blood glucose, glycated haemoglobin (HbA 1c ), insulin levels, insulin resistance and the improvement of HDL levels and fasting blood glucose. 32 Resveratrol supplementation has also been shown to reduce body weight, lower systolic blood pressure and to beneficially moderate total cholesterol, HDL:LDL ratios and to lower triglycerides and urea nitrogen. It also significantly increases the levels of endogenous antioxidant enzymes, 33, 34 lowers insulin resistance and urinary ortho-tyrosine excretion and increases the platelet ratio of phosphorylated protein kinase B (pAkt) protein to kinase B (Akt) protein (pAkt:Akt). Akt is a serine-threonine kinase that mediates a number of cellular processes including vascular endothelial growth factor (VEGF) expression and insulin sensitivity by improving insulin signalling.
Resveratrol is also associated with improvements in glycaemic and lipid parameters in obese individuals. [32] [33] [34] [35] Resveratrol modifies adipokine expression via inhibition of the inflammatory response, thereby reducing insulin resistance by activating SIRT1, which is the principal modulator that produces a beneficial effect on glucose homeostasis and insulin sensitivity. 36 It also restores endogenous antioxidant manganese superoxide dismutase (MnSOD) function independent of sirtuin activation. 12 Resveratrol appears to lower insulin resistance via the inhibition of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB), a redoxsensitive transcription factor and peroxisome proliferator-activated receptor gamma (PPARg). Resveratrol's inhibition of NF-kB operates to downregulate the pancreatic b-cell apoptotic pathway resulting in improved b-cell survival, 37 and exhibits an antioxidant independent protective effect against diabetic neuropathy.
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Resveratrol increases NAD+ levels via upregulation of the NAD+ synthetic enzyme nicotinamide mononucleotide adenyltransferease. 39 Maintaining physiological NAD+ levels is essential for normal cellular Although the full range of effects of mTORC1 activity on adult metabolic disorders, including type 2 diabetes, is an exceedingly complex matter, it does appear, based on some in vivo evidence, that inhibition of mTORC1 plays a constitutive role in the beneficial attenuation of insulin resistance and diabetic nephropathy.
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Resveratrol and Cardiovascular Protection
Resveratrol, as a component, is believed to be responsible for the 'French Paradox', namely low mortality due to coronary heart disease as a result of moderate consumption of red wine by the French. Both the preclinical and clinical data, shown in Tables 1 and 2 , as well as a large and growing body of additional in vitro and in vivo evidence, clearly reinforce this theory and suggest that resveratrol also plays a crucial role in cardiovascular disease (CVD) protection. 44, 45 Wine also contains a relatively high level of nonstilbene phytochemicals, which are thought to potentiate the beverage's chemo-preventative properties in terms of CVD and other chronic diseases often associated with ageing and obesity in the general population.
Resveratrol and Diabetic Retinopathy
One of the more devastating pathophysiological sequelae of protracted glycaemic instability is the degradation of vision resulting from acute retinopathy. Retinopathy is one of the leading causes of blindness among adult populations worldwide. 46 The condition is characterised by the propagation of abnormal, profuse microvascularity and concurrent capillary fibrosis, which precipitate occulsion of the retina and optic disc.
Overexpression of the angiogenesis regulator, VEGF, has been implicated as a major promoter in the proliferation of these dysfuntional vascular structures. Aberrant angiogenesis and macular oedema are cofactors principally responsible for the progressive loss of visual acuity, which can advance in a relatively brief time to blindness. 47, 48 Inflammation also appears to play a significant contributory role in the development of retinal pathologies. 49 Resveratrol is a non-invasive, multi-modal, chemo-preventative agent with the ability to prevent or impede the onset and development of diabetic retinopathy. Resveratrol attenuates the progression of retinopathy by suppressing angiogenesis, 50,51 inhibiting inflammation 52 and downregulating neuronal apoptosis. 53 In its capacity as a potent small molecule antioxidant, resveratrol counters oxidative stress. 54 Finally, this phytochemical operates to block the vascular lesions as well as the endothelial hyperpermeabiity, which cause capillary leakage and loss of pericytes. 55, 56 Resveratrol's inhibition of VEGF appears to be one of the main modalities via which the molecule exerts a potentially therapeutic reduction of a number of the principal initiators and mediators of retinopathy.
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Safety and Tolerability of Resveratrol
Resveratrol is well tolerated in both young and older humans, and does not cause any serious adverse effects in subjects on doses of up to 5 g per day. Neither have toxicity or adverse effects been observed at higher doses; however, limited data exist upon which to base any definitive conclusions relative to doses higher than 5 g per day. It is safe as revealed by lack of serious adverse events detected by clinical, biochemical and haematological indices during intervention and a two-week follow up. 58, 59 Nearly 90 % of all reported adverse effects can be classified as grades 1 or 2 according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), with many being mild and transient.
Conclusion
Resveratrol has been shown to be effective in modulating blood glucose levels, decreasing insulin resistance, inhibiting chronic inflammation, improving blood lipid profiles, attenuating diabetic hypertension and countering odixative stress. Resveratrol may also play a role in the prevention or retardation of diabetes-related comorbidities and complications.
The biological processes, signalling pathways, proteomics and biochemical modalities via which resveratrol operates have been extensively investigated and are relatively well identified and defined. The therapeutic effects of this phytoalexin appear to include a significant improvement of an array of relevant metrics including improvement of insulin sensitivity, modulation of blood glucose levels, cardiovascular protection, attenuation of diabetic hypertension, inhibition of oxidative stress and chronic inflammation, improvement of blood lipid profiles and support of retinal health.
Major challenges remain concerning the safety and efficacy of chronic resveratrol administration as well as optimal doses, due to the wellknown hormetic actions of the compound, which demonstrates protective properties at lower doses and detrimental effects at higher doses. Furthermore, although resveratrol administration shows beneficial effects, its molecular mechanisms of action are only partially known. It is well known that resveratrol is rapidly metabolised and conjugated with glucuronic acid and sulphate due to the action of uridine 5'-diphospho-glucuronosyltransferase (UDP-glucuronosyl-transferase) and sulphotransferases and these are the major circulating forms of this molecule, both in humans and experimental models. However, the biological activity of these active metabolites needs to be elucidated fully. Indeed, the majority of in vitro available data have been obtained by employing the unconjugated form of resveratrol, at concentrations that largely exceed those that can be reached in vivo, at both plasma and tissue levels. 
